Bengaluru-based Immuneel Therapeutics, a pioneering cell and gene therapy platform, has announced the appointment of Amit Mookim as its new Chief Executive Officer (CEO). Mookim brings over two decades of extensive experience across life sciences, technology and private equity, making him ideally suited to lead Immuneel into its next phase of growth and innovation.
Mookim joins Immuneel from IQVIA, a Fortune 500 global leader in clinical research, technology and analytics, where he served as Managing Director for South Asia. At IQVIA, he played a pivotal role in integrating two large organisations post-merger, overseeing the site operations for a combined workforce of 20,000+ professionals across India. His leadership was instrumental in growing the South Asia commercial business both organically and inorganically.
Prior to his tenure at IQVIA, Mookim was Head of Healthcare at KPMG India. He built KPMG’s healthcare business from the ground up and worked extensively with leading hospitals, PE funds and international healthcare companies to establish and grow their presence in India. His deep expertise in healthcare transactions, M&A, and private equity investments positioned him as a thought leader in the industry. Mookim possesses significant experience in developing innovative business models and supporting entrepreneurship in the healthcare industry.
